AU2018234056B2 - Subcutaneous administration of a P2Y12 receptor antagonist - Google Patents

Subcutaneous administration of a P2Y12 receptor antagonist Download PDF

Info

Publication number
AU2018234056B2
AU2018234056B2 AU2018234056A AU2018234056A AU2018234056B2 AU 2018234056 B2 AU2018234056 B2 AU 2018234056B2 AU 2018234056 A AU2018234056 A AU 2018234056A AU 2018234056 A AU2018234056 A AU 2018234056A AU 2018234056 B2 AU2018234056 B2 AU 2018234056B2
Authority
AU
Australia
Prior art keywords
receptor antagonist
administered
pharmaceutically acceptable
acceptable salt
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018234056A
Other languages
English (en)
Other versions
AU2018234056A1 (en
Inventor
Martine BAUMANN
Markus KRAMBERG
Markus REY
Markus Riederer
Sebastien Roux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viatris Asia Pacific Pte Ltd
Original Assignee
Viatris Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Asia Pacific Pte Ltd filed Critical Viatris Asia Pacific Pte Ltd
Publication of AU2018234056A1 publication Critical patent/AU2018234056A1/en
Application granted granted Critical
Publication of AU2018234056B2 publication Critical patent/AU2018234056B2/en
Assigned to VIATRIS ASIA PACIFIC PTE. LTD. reassignment VIATRIS ASIA PACIFIC PTE. LTD. Request for Assignment Assignors: IDORSIA PHARMACEUTICALS LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018234056A 2017-03-15 2018-03-14 Subcutaneous administration of a P2Y12 receptor antagonist Active AU2018234056B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017056175 2017-03-15
EPPCT/EP2017/056175 2017-03-15
PCT/EP2018/056372 WO2018167139A1 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a p2y12 receptor antagonist

Publications (2)

Publication Number Publication Date
AU2018234056A1 AU2018234056A1 (en) 2019-10-31
AU2018234056B2 true AU2018234056B2 (en) 2023-05-25

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018234056A Active AU2018234056B2 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a P2Y12 receptor antagonist

Country Status (18)

Country Link
US (1) US11179390B2 (enExample)
EP (1) EP3595666A1 (enExample)
JP (2) JP7580918B2 (enExample)
KR (1) KR102510832B1 (enExample)
CN (1) CN110381947A (enExample)
AU (1) AU2018234056B2 (enExample)
BR (1) BR112019014567A2 (enExample)
CL (1) CL2019002318A1 (enExample)
EA (1) EA201992123A1 (enExample)
IL (1) IL269286B2 (enExample)
MA (1) MA49887A (enExample)
MX (1) MX393334B (enExample)
MY (1) MY205605A (enExample)
PH (1) PH12019502111A1 (enExample)
SG (1) SG11201908128YA (enExample)
TW (1) TWI765002B (enExample)
UA (1) UA125531C2 (enExample)
WO (1) WO2018167139A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式
TWI905227B (zh) * 2020-07-15 2025-11-21 新加坡商暉致亞太私人有限公司 包含p2y12受體拮抗劑的水性醫藥組合物
CA3223733A1 (en) 2021-07-13 2023-01-19 Nicole Blumer A process for the synthesis of 4-((r)-2-{[6-((s)-3-methoxy-pyrrolidin-1-yl)-2-phenyl- pyrimidine-4-carbonyl]-amino}-3-phosphono-propionyl)-piperazine-1 -carboxylic acid butyl ester
CN118871446A (zh) 2022-03-14 2024-10-29 晖致亚太私人有限公司 (r)-2-((叔丁氧基羰基)氨基)-3-(二乙氧基磷酰基)丙酸或其膦酸酯衍生物的合成方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
CA2375920A1 (en) 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
CN1747732A (zh) 2002-12-11 2006-03-15 舍林股份公司 作为血小板腺苷二磷酸受体拮抗剂的2－氨基羰基喹啉化合物
WO2004092189A1 (en) 2003-04-09 2004-10-28 Wyeth Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
WO2005002574A1 (en) 2003-06-24 2005-01-13 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
ES2421448T3 (es) 2005-10-21 2013-09-02 Actelion Pharmaceuticals Ltd Derivados de piperazina como agentes contra la malaria
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2684644A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
US20090048216A1 (en) 2007-05-02 2009-02-19 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
RU2483072C2 (ru) 2007-11-29 2013-05-27 Актелион Фармасьютиклз Лтд Производные фосфоновой кислоты и их применение в качестве антагонистов рецептора p2y12
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
MX2011010200A (es) 2009-04-08 2011-10-14 Actelion Pharmaceuticals Ltd 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp).
JP5536876B2 (ja) 2009-04-22 2014-07-02 アクテリオン ファーマシューティカルズ リミテッド チアゾール誘導体及びｐ２ｙ１２受容体拮抗剤としてのそれらの使用
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2585161A1 (en) 2010-06-23 2013-05-01 Stefan Kralev Medical device for self-administration of patients with acute coronary events
CN109715639B (zh) 2016-09-22 2022-04-19 爱杜西亚药品有限公司 结晶形式

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. Baldoni, et al.; "A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial", Clin. Drug Investig. 2014, 34(11): 807-818. *
E. Caroff, et al.; "4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug", J. Med. Chem. 2015, 58(23): 9133-9153. *

Also Published As

Publication number Publication date
CL2019002318A1 (es) 2020-01-10
JP2020510043A (ja) 2020-04-02
US20200129510A1 (en) 2020-04-30
JP2023052576A (ja) 2023-04-11
IL269286B2 (en) 2023-08-01
MA49887A (fr) 2020-06-24
IL269286A (en) 2019-11-28
MX2019009559A (es) 2019-10-15
KR20190124297A (ko) 2019-11-04
WO2018167139A1 (en) 2018-09-20
JP2025060907A (ja) 2025-04-10
MX393334B (es) 2025-03-24
MY205605A (en) 2024-10-29
IL269286B1 (en) 2023-04-01
SG11201908128YA (en) 2019-10-30
UA125531C2 (uk) 2022-04-13
AU2018234056A1 (en) 2019-10-31
TW201840323A (zh) 2018-11-16
NZ757938A (en) 2024-07-05
EP3595666A1 (en) 2020-01-22
BR112019014567A2 (pt) 2020-02-18
JP7580918B2 (ja) 2024-11-12
TWI765002B (zh) 2022-05-21
PH12019502111A1 (en) 2020-03-16
CA3050831A1 (en) 2018-09-20
CN110381947A (zh) 2019-10-25
JP7902762B2 (ja) 2026-08-10
KR102510832B1 (ko) 2023-03-15
EA201992123A1 (ru) 2020-02-25
US11179390B2 (en) 2021-11-23

Similar Documents

Publication Publication Date Title
JP2023052576A (ja) Ｐ２ｙ１２受容体アンタゴニストの皮下投与
ES3064585T3 (en) Nicorandil derivatives
KR20180032578A (ko) 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도
EP3380095A1 (en) Compositions and methods for treating ischemic stroke
EP4592294A1 (en) Novel carbamate compound and use thereof
US9750785B2 (en) Vasopressin formulations for use in treatment of hypotension
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
CA3050831C (en) Subcutaneous administration of a p2y12 receptor antagonist
US9308174B2 (en) Lyophilized formulations of bendamustine hydrochloride
TWI905227B (zh) 包含p2y12受體拮抗劑的水性醫藥組合物
JP2023082167A (ja) 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
EA042138B1 (ru) Подкожное введение антагониста p2y12 рецептора
Thakur¹ et al. Review on chemistry and pharmacology of dabigatran a potent anticoagulant
HK40094173A (en) Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
HK40094173B (en) Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VIATRIS ASIA PACIFIC PTE. LTD.

Free format text: FORMER OWNER(S): IDORSIA PHARMACEUTICALS LTD